Table 3. Multivariate Cox proportional-hazards analysis of A. disease-free survival and B. overall survival for patients with resected stage II/III CRC according to age-adjusted RTL of normal mucosa (nRTL), cancer (cRTL) and cRTL/nRTL ratio.
| A. Disease-free survival | nRTL | cRTL | cRTL/nRTL | |||||
|---|---|---|---|---|---|---|---|---|
| n | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||
| Relative telomere length | ||||||||
| T/S ratio | 246 | 0.77 (0.42 - 1.42) | 0.411 | 0.82 (0.47 - 1.45) | 0.502 | 0.89 (0.66 - 1.20) | 0.451 | |
| Age | ||||||||
| Years | 246 | 0.99 (0.96 - 1.02) | 0.374 | 0.99 (0.96 - 1.02) | 0.483 | 0.99 (0.96 - 1.02) | 0.469 | |
| Gender | ||||||||
| Male | 124 | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Female | 122 | 0.61 (0.35 - 1.07) | 0.087 | 0.62 (0.35 - 1.10) | 0.102 | 0.61 (0.35 - 1.08) | 0.089 | |
| Tumor site | ||||||||
| Proximal colon | 116 | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Distal colon | 94 | 0.80 (0.42 - 1.51) | 0.486 | 0.83 (0.44 - 1.57) | 0.564 | 0.84 (0.44 - 1.58) | 0.585 | |
| Rectum | 36 | 1.05 (0.49 - 2.25) | 0.905 | 1.05 (0.49 - 2.27) | 0.898 | 1.05 (0.49 - 2.27) | 0.900 | |
| Tumor stage | ||||||||
| II | 130 | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| III | 116 | 3.06 (1.47 - 6.37) | 0.003* | 3.11 (1.49 - 6.47) | <0.001* | 3.16 (1.52 - 6.59) | 0.002* | |
| Differentiation | ||||||||
| Well/Moderate | 188 | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Poor | 58 | 2.57 (1.48 - 4.46) | 0.001* | 2.61 (1.51 - 4.54) | <0.001* | 2.63 (1.51 - 4.57) | 0.001* | |
| Adjuvant chemotherapy | ||||||||
| No | 108 | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Yes | 138 | 1.51 (0.72 - 3.16) | 0.279 | 1.48 (0.71 - 3.11) | 0.299 | 1.47 (0.70 - 3.10) | 0.307 | |
| B. Overall survival | ||||||||
| Relative telomere length | ||||||||
| T/S ratio | 281 | 0.82 (0.45 - 1.48) | 0.506 | 1.15 (0.77 - 1.74) | 0.493 | 0.99 (0.75 - 1.32) | 0.944 | |
| Age | ||||||||
| Years | 281 | 1.03 (1.00 - 1.06) | 0.026* | 1.03 (1.00 - 1.06) | 0.035* | 1.03 (1.00 - 1.06) | 0.028* | |
| Gender | ||||||||
| Male | 146 | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Female | 135 | 0.57 (0.33 - 0.98) | 0.044* | 0.56 (0.32 - 0.96) | 0.035* | 0.57 (0.33 - 0.98) | 0.041* | |
| Tumor site | ||||||||
| Proximal colon | 132 | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Distal colon | 101 | 0.54 (0.29 - 1.02) | 0.056 | 0.56 (0.30 - 1.04) | 0.066 | 0.56 (0.30 - 1.04) | 0.067 | |
| Rectum | 48 | 0.86 (0.43 - 1.70) | 0.660 | 0.88 (0.44 - 1.76) | 0.724 | 0.87 (0.44 - 1.72) | 0.682 | |
| Tumor stage | ||||||||
| II | 143 | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| III | 138 | 2.97 (1.60 - 5.52) | 0.001* | 3.01 (1.62 - 5.58) | <0.001* | 3.00 (1.61 - 5.58) | 0.001* | |
| Differentiation | ||||||||
| Well/Moderate | 215 | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Poor | 66 | 2.01 (1.18 - 3.41) | 0.010* | 2.05 (1.21 - 3.48) | 0.007* | 2.06 (1.21 - 3.51) | 0.007* | |
| Adjuvant chemotherapy | ||||||||
| No | 121 | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Yes | 160 | 1.10 (0.59 - 2.05) | 0.767 | 1.11 (0.59 - 2.07) | 0.750 | 1.10 (0.59 - 2.06) | 0.761 | |
*
P<0.05